Gilead Sciences, Inc. (GILD) operating KPIs
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.68+5.07 (+3.06%)
Close on Oct 30, 2026Market cap $211.64BP/E –Yield 1.85%
Gilead Sciences consolidated revenues — Other countries (legacy breakout, $M) ($M)
Form 10-K Segment & Geographic Information
Latest, FY2017
2,602
Period ended Dec 31, 2017
Change on a year earlier
-44.3%
4,671 in FY2016
History
4 years
Since FY2014
Sources
2
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Consolidated revenues — Other countries (legacy breakout, $M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2017 | Dec 31, 2017 | 2,602 | -44.3% | Form 10-K (filed 2018-02-27) ↗ |
| FY2016 | Dec 31, 2016 | 4,671 | +20.5% | Form 10-K (filed 2018-02-27) ↗ |
| FY2015 | Dec 31, 2015 | 3,877 | +219.6% | Form 10-K (filed 2018-02-27) ↗ |
| FY2014 | Dec 31, 2014 | 1,213 | – | Form 10-K (filed 2017-02-27) ↗ |
Cite this data
StockData. (2026). Gilead Sciences Consolidated revenues — Other countries (legacy breakout, $M) ($M), annual FY2014–FY2017 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/geo_rev_other_cty
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.